Streetbeat News

Products Services

CLDI

Baird has initiated coverage on Calidi Biotherapeutics Inc (NYSE:CLDI) with an Outperform rating and a price target of $9. The company, which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment, recently went public via a SPAC. Early clinical data of its lead agent CLD-101 showed promising results in glioma patients. However, the company is operating with a brief cash runway of approximately 12 months, which is exerting downward pressure on the stock.

Portfolio Pulse from Vandana Singh

October 09, 2023 | 6:21 pm

PRME

BMO Capital Markets has initiated coverage on Prime Medicine Inc (NASDAQ:PRME), a preclinical-stage company developing therapies based on prime editing. The analyst, Kostas Biliouris, has given an Outperform rating with a price target of $19, citing the high specificity and versatility of prime editing. Prime's pipeline includes diversified therapies targeting different tissues and delivered via distinct methods, reducing overall risk. The company's lead program aims to provide a gene editing therapy for chronic granulomatous disease (CGD), with an IND filing planned for 2024.

Portfolio Pulse from Vandana Singh

October 09, 2023 | 6:19 pm

ATVI

MSFT

Concerns about cheating in the Modern Warfare 3 beta, particularly on the PlayStation 5 version, are escalating among Call of Duty fans. The extent of the cheating remains unclear, but videos showcasing apparent cheating have raised concerns about the future of competitive play. Activision Blizzard Inc (NASDAQ:ATVI) aims to address this with its new anti-cheat system called Ricochet. Microsoft Corp (NASDAQ:MSFT) is nearing the completion of its $69 billion acquisition of parent company Activision Blizzard.

Portfolio Pulse from Franca Quarneti

October 09, 2023 | 6:10 pm

MSFT

The Xbox-exclusive game 'Redfall' is receiving a major update, including a 60 FPS mode for Xbox Series X/S and various gameplay improvements. Despite its troubled launch, Microsoft and Bethesda remain committed to supporting the game in the long term. The game still faces challenges, with a small player base on Steam.

Portfolio Pulse from Franca Quarneti

October 09, 2023 | 5:53 pm

LYV

Benchmark analyst Matthew Harrigan reiterated a Buy rating on Live Nation Entertainment Inc (NYSE:LYV) with a price target of $110. The company is praised for its innovation in technology for music experiences and its ticketing platform. Live Nation recently announced the end of all merchandise fees and is offering $1,500 stipends for club headliners. The company-owned Veep launched a subscription service for fans to access livestream shows and on-demand replays.

Portfolio Pulse from Shivani Kumaresan

October 09, 2023 | 5:46 pm

BYDDF

NIO

TSLA

NIO Inc's shares are trading lower due to strong sales numbers from China-based EV competitors. The China Passenger Car Association data shows that BYD Co, backed by Warren Buffett, is the biggest player in China, delivering 286,903 vehicles in September, up 40% YoY. Nio delivered 15,641 vehicles in September, with Q3 deliveries totaling 55,432. Nio lost about $35,000 per vehicle last quarter as it continues to invest in R&D. Nio shares are down about 16% since the start of the year.

Portfolio Pulse from Adam Eckert

October 09, 2023 | 5:35 pm

SEDG

SolarEdge Technologies has announced that all of its manufacturing lines, support infrastructure, as well as sales and R&D teams globally are operational.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 5:30 pm

MRVL

NVDA

OpenAI is reportedly considering building its own AI accelerator and diversifying its suppliers beyond Nvidia (NVDA). Despite this, Citi analyst Atif Malik predicts that Nvidia will maintain a ~90% share in the AI GPU market for the next 2-3 years. Marvell Technology (MRVL) is another AI player potentially looking to build its own AI accelerator.

Portfolio Pulse from Anusuya Lahiri

October 09, 2023 | 4:58 pm

ZTS

Zoetis has announced the U.S. commercial launch of Librela, an anti-NGF monoclonal antibody treatment for canine osteoarthritis pain, and Apoquel Chewable, a treatment for pruritus associated with allergic dermatitis and atopic dermatitis in dogs. Both products are firsts in their respective categories and aim to improve treatment compliance and quality of life for dogs.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 4:50 pm

BNTX

CAH

CVS

MCK

MRNA

PFE

WBA

WMT

The US government has shifted responsibility for COVID-19 vaccine distribution and payment coverage to private companies, leading to upfront payment requests. Pfizer, BioNTech, Moderna, CVS Health Corp, Walmart, Walgreens Boots Alliance, McKesson Corporation, and Cardinal Health are involved in the distribution. Some individuals have reported that pharmacies are not covering the new vaccine doses at their locations.

Portfolio Pulse from Vandana Singh

October 09, 2023 | 4:40 pm